GlassScriptPhysician profile
Wynette Adele Almeida
NPI 1518550268
$4,342.56
in general payments reported to CMS, 2019-2025
30 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $1,521 · 2023: $652 · 2024: $615 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.43 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $662.66 | 2021-2025 | Darzalex, Tecvayli, Tremfya |
| Daiichi Sankyo INC. | $428.46 | 2021-2025 | Enhertu |
| Eisai INC. | $363.26 | 2021-2025 | |
| Seagen INC. | $313.96 | 2021-2023 | Padcev |
| Pfizer INC. | $285.73 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $268.91 | 2021-2023 | Fotivda |
| Abbvie INC. | $257.95 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $206.39 | 2021-2024 | Keytruda |
| Sanofi-Aventis U.S. LLC | $198.95 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $195.16 | 2021-2022 | |
| Foundation Medicine, INC. | $137.94 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.83 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $118.82 | 2023 | Imbruvica |
| Dendreon Pharmaceuticals LLC | $76.10 | 2021-2023 | Provenge |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $71.63 | 2022-2024 | |
| Myovant Sciences INC. | $69.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.65 | 2023 | |
| Gilead Sciences, INC. | $31.37 | 2025 | Trodelvy |
| Astellas Pharma US INC | $26.61 | 2024 | Padcev |
| Sumitomo Pharma America, INC. | $23.25 | 2023 | Orgovyx |
| Puma Biotechnology, INC. | $22.95 | 2025 | |
| Aimmune Therapeutics, INC. | $22.74 | 2025 | Vowst |
| Celgene Corporation | $22.61 | 2023 | |
| Immunogen, INC. | $22.27 | 2023 | Elahere |
| Ardelyx, INC. | $21.99 | 2025 | Ibsrela |
| Tersera Therapeutics LLC | $21.82 | 2025 | Zoladex |
| Emd Serono, INC. | $21.61 | 2022 | |
| Amgen INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wynette Almeida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.